Pharmaceutical giant Merck & Co.'s stock closed at $148.69 on September 28, 2026, after a 0.06% decline from its previous close.
The company announced an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D inhibitor.
This deal marks another significant move in Merck's efforts to expand its portfolio and address pressing medical needs.
More on Stocks
Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.
Market sentiment intelligence for apps, funds & agents
Location
729 55 Ave SW
Calgary AB T2V 0G4
Canada
Navigate
© 2026 Guavy Inc
